Tag Archives: antipsychotics

Pharma Backed Australian of the Year Psychiatrist Wants Millions in Government Funding for Brave New World of “Pre-Drugging” Kids

Who is Patrick McGorry and what does he promote? He’s a psychiatrist just named Australian of the Year for his work in “youth mental health reform.” What does that reform consist of? What he calls a “new form of climate change.” It sure is. He not only promotes youths being put on antipsychotics and antidepressants, cited by international drug regulatory agencies as causing hallucinations, hostility, personality change, life-threatening diabetes, strokes, suicide and death, McGorry goes a giant step further—drug them before they’ve even developed a “psychiatric” disorder. The Association for the Accreditation of Human Research Protection Programs (AHRPP) likens such concepts to “performing mastectomies on women who are at risk of—but do not have—breast cancer.”

Lawyer who took on drug giant Eli Lilly & won has a new target—the psychiatric industry & drugging of foster kids

An Alaska attorney who has gone up against a drug giant and won has a new target. Jim Gottstein is taking on psychiatry in Alaska for over-prescribing medicine to children. Gottstein was the attorney who forced Eli Lilly to pay more than $1 billion in settlements over the anti-psychotic drug Zyprexa. He also heads up a group called the Law Project for Psychiatric Rights, which filed the lawsuit. The group claims over-prescribing is disabling children for life.

Kickbackers’ motto: ‘Do no harm’ (to profits)—How drug company used kickbacks to get patients on psych drugs

TALK ABOUT death panels. The US attorney in Boston recently filed suit against the world’s largest maker of health products, Johnson & Johnson, for using kickbacks to get more nursing home patients onto its drugs, including one that was later found to be so lethal to the elderly it had to carry a black-box warning. The government’s complaint leaves little doubt that the drug company acted in a predatory way to increase sales and market share for its products, especially Risperdal, an antipsychotic often used to keep Alzheimer’s and dementia patients under control.